News und Analysen
![Charles River Launches First Annual Healthcare Collaboration Report](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Charles River Launches First Annual Healthcare Collaboration Report
Charles River Laboratories International, Inc. (NYSE: CRL) today released the results from its first annual Healthcare Collaboration Report, which identified Americans’ perceptions of healthcare’s
![Clovis Oncology Retires Remaining 2021 Notes and Raises Additional Capital through its ATM Equity Offering Program : https://mms.businesswire.com/media/20191107005162/en/305545/5/Clovis_Logo_Process_Color.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOTRqRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--8c255f1cb7b73806f677f1d1d64e93866d2979a5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Clovis_Logo_Process_Color.jpg?locale=de)
Clovis Oncology Retires Remaining 2021 Notes and Raises Additional Capital through its ATM Equity Offering Program
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has paid off in full at maturity the remaining $64.4 million in principal amount outstanding of its 2.50% convertible senior notes due
![Pfizer and BioNTech Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Yearshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=de)
Pfizer and BioNTech Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from a Phase 2/3 trial showing a favorable safety profile and robust neutralizing antibody responses in children 5 to
![FDA Advisory Committee Votes Unanimously in Favor Of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-risk Populationshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=de)
FDA Advisory Committee Votes Unanimously in Favor Of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-risk Populations
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted
![Navidea Biopharmaceuticals Announces Changes to Board of Directors Composition: https://mms.businesswire.com/media/20191107006076/en/389794/5/navidea_cmyk.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNllsRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--8f98c3cfd17bc93aed823f932a665c78f3f036eb/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/navidea_cmyk.jpg?locale=de)
Navidea Biopharmaceuticals Announces Changes to Board of Directors Composition
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
![Deciphera Pharmaceuticals Presents New Clinical Study Results Across Pipeline at the European Society for Medical Oncology (ESMO) Congress 2021](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Deciphera Pharmaceuticals Presents New Clinical Study Results Across Pipeline at the European Society for Medical Oncology (ESMO) Congress 2021
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced four
![Geisinger and Acadia Healthcare Hold Groundbreaking Ceremony for New Behavioral Health Center in Moosic](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Geisinger and Acadia Healthcare Hold Groundbreaking Ceremony for New Behavioral Health Center in Moosic
Geisinger and Acadia Healthcare Company today held a groundbreaking ceremony for Geisinger Behavioral Health Center Northeast, a new 96-bed inpatient behavioral health facility. The event occurred
![BIOCORP und MERCK unterzeichnen Kooperationsvereinbarung auf dem Gebiet des menschlichen Wachstumshormons (HGH): https://mms.businesswire.com/media/20191211005828/en/639213/5/Logo_Biocorp.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNVAxRmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--27e0b79ca4263b2c37c92a647381d83a6cd1d5c8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Logo_Biocorp.jpg?locale=de)
BIOCORP und MERCK unterzeichnen Kooperationsvereinbarung auf dem Gebiet des menschlichen Wachstumshormons (HGH)
Aufsichtsrechtliche Meldungen:
BIOCORP (FR0012788065 – ALCOR / PEA/KMU-qualifiziert), ein französisches Unternehmen, das auf die Konzeption, Entwicklung und Herstellung von innovativen
![Newron Announces Half-Year 2021 Results : https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBelB3SXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--521237387ec8207326f44117d145b81c1391bc28/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/logo_color_high_res.jpg?locale=de)
Newron Announces Half-Year 2021 Results
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral
![Transgene Presents Data From Phase I Clinical Trial Confirming the Potential of the Oncolytic Virus TG6002 : https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOFo2Rmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--73fe07bc16ac0607e1cc0e1a0b34e650fa94b07d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/logo_TRANSGENE.jpg?locale=de)
Transgene Presents Data From Phase I Clinical Trial Confirming the Potential of the Oncolytic Virus TG6002
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces the presentation of data
![Vifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMndsRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--37beee983e668f5de331d0d69e2c6f07f1240d69/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/VP_logo_rgb.jpg?locale=de)
Vifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210915005966/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor
![BIOCORP and MERCK Sign a Partnership in the Field of Human Growth Hormone (HGH): https://mms.businesswire.com/media/20191211005828/en/639213/5/Logo_Biocorp.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNVAxRmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--27e0b79ca4263b2c37c92a647381d83a6cd1d5c8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Logo_Biocorp.jpg?locale=de)
BIOCORP and MERCK Sign a Partnership in the Field of Human Growth Hormone (HGH)
Regulatory News:
BIOCORP (FR0012788065 – ALCOR / Eligible PEA PME), a French company specialized in the design, development, and manufacturing of innovative medical devices, and Merck, a leading
![Aurinia Pharmaceuticals to Present at Upcoming September Investor Conferences : https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeThpRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5d91333dbb55b274fa0400e435af0453aa80c824/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Aurinia-logo-web-700px.jpg?locale=de)
Aurinia Pharmaceuticals to Present at Upcoming September Investor Conferences
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the senior management team will present at the following upcoming virtual investor conferences:
![Simulations Plus Releases ADMET Predictor® (X.3): https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNEFWS2c9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ff1977c5f19c19899ef789fb8e692387f41c81f2/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/BusinessWireLogo.jpg?locale=de)
Simulations Plus Releases ADMET Predictor® (X.3)
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it
![GenSight Biologics Announces Positive Data Safety Monitoring Board Review of PIONEER Phase I/II Clinical Trial of GS030 as Optogenetic Treatment for Retinitis Pigmentosa: https://mms.businesswire.com/media/20191208005050/en/761225/5/Logo+Centre+Hospitalier+XV-XX.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMXBqRmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--32e5498581c41f5af17897302b60481289223182/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Logo+Centre+Hospitalier+XV-XX.jpg?locale=de)
GenSight Biologics Announces Positive Data Safety Monitoring Board Review of PIONEER Phase I/II Clinical Trial of GS030 as Optogenetic Treatment for Retinitis Pigmentosa
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
![Sensorion And Hearing Care Leader Sonova Sign Strategic Research Collaboration: https://mms.businesswire.com/media/20210609005851/en/705797/5/logo-sensorion2.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK0dxVmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--df3db62501cd2dac51e6a4832a420790d1de65b6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/logo-sensorion2.jpg?locale=de)
Sensorion And Hearing Care Leader Sonova Sign Strategic Research Collaboration
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN), a pioneering clinical-stage biotech company specializing in the development of novel therapies to restore, treat, and prevent
![Hanger to Present at the Baird 2021 Global Healthcare Conference](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Hanger to Present at the Baird 2021 Global Healthcare Conference
Hanger, Inc. (NYSE: HNGR), a leading provider of orthotic and prosthetic patient care services and solutions, announced today that members of its management team will participate virtually in
![Waters BioAccord System with ACQUITY Premier Brings Greater Simplicity, Accuracy and Reproducibility to Multi-Attribute Monitoring of Biopharmaceuticals](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Waters BioAccord System with ACQUITY Premier Brings Greater Simplicity, Accuracy and Reproducibility to Multi-Attribute Monitoring of Biopharmaceuticals
Waters Corporation (NYSE:WAT) today introduced the Waters™ BioAccord™ System with ACQUITY™ Premier, a combination of the Waters BioAccord System and the breakthrough ACQUITY Premier UPLC™ with
![Novocure Announces Clinical Trial Collaboration with Roche to Evaluate Tumor Treating Fields as Part of a Novel Combination for the First-line Treatment of Metastatic Pancreatic Cancer: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBLzJBRWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5cbb888b15fc1babe89717dad3b9d241825019eb/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/novocure_main-405x.jpg?locale=de)
Novocure Announces Clinical Trial Collaboration with Roche to Evaluate Tumor Treating Fields as Part of a Novel Combination for the First-line Treatment of Metastatic Pancreatic Cancer
Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with Roche (SIX: RO. ROG; OTCQX: RHHBY), to develop Tumor Treating Fields (TTFields) together
![Non-insured Health Benefits Program Now Covers Dexcom G6 Continuous Glucose Monitoring System for Children and Adolescents on Intensive Insulin Therapy](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Non-insured Health Benefits Program Now Covers Dexcom G6 Continuous Glucose Monitoring System for Children and Adolescents on Intensive Insulin Therapy
Dexcom, Inc. (NASDAQ: DXCM), a leader in real-time continuous glucose monitoring (CGM), is pleased to announce the Dexcom G6 CGM System is now covered by the Non-Insured Health Benefits (NIHB)
![Transgene Announces Upcoming Investor Meetings: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOFo2Rmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--73fe07bc16ac0607e1cc0e1a0b34e650fa94b07d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/logo_TRANSGENE.jpg?locale=de)
Transgene Announces Upcoming Investor Meetings
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces that Management will participate in
![Aurinia Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeThpRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5d91333dbb55b274fa0400e435af0453aa80c824/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Aurinia-logo-web-700px.jpg?locale=de)
Aurinia Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the senior management team will participate in the H.C. Wainwright & Co. 23rd Annual Global Investment
![NanoString to Webcast Presentation from the Baird 2021 Global Healthcare Conference: https://mms.businesswire.com/media/20191104005218/en/753909/5/NSTG-Logo-19-%28002%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBLzhpRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b6ef578a6eaa604de21c95a83c7b989a1a3263c9/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/NSTG-Logo-19--28002-29.jpg?locale=de)
NanoString to Webcast Presentation from the Baird 2021 Global Healthcare Conference
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast a
![Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital as of August 31, 2021: https://mms.businesswire.com/media/20191111005579/en/744572/5/LOGO_NANO_EXPANDING_LIFE.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM25oRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--fb25377a8ea9e69d3b62f03b482ed70fb95efba1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/LOGO_NANO_EXPANDING_LIFE.jpg?locale=de)
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital as of August 31, 2021
Regulatory News:
Nanobiotix (Paris:NANO) (NASDAQ:NBTX):
Market: Euronext Paris
Compartment: B
ISIN code: FR0011341205
Website: www.nanobiotix.com
Date
Number of Shares
Outstanding
![Valbiotis Releases its Letter to Shareholders for 2021: https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNXFzSVE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--15bfdf03f8ab493929a3d2392e314697d3469f59/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/valbiotis-logo.jpg?locale=de)
Valbiotis Releases its Letter to Shareholders for 2021
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible) (Paris:ALVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic